Pinealon

• Pinealon (Glu-Asp-Arg, 'EDR') is a synthetic tripeptide 'bioregulator' from the Russian Khavinson short-peptide tradition, marketed for neuroprotection and cognitive enhancement.
• Its signature mechanistic claim — that the peptide directly binds DNA to modulate gene expression — is a hallmark of this family and is NOT well established in mainstream literature. Read it skeptically.
• The evidence is predominantly Russian-authored animal/cell work; a frequently cited '72-patient TBI study' isn't among the verifiable preclinical references and needs independent confirmation.
• It is not FDA-approved, and the published safety data is sparse.

Pinealon is one of the 'short peptide bioregulators' developed in Russia under Vladimir Khavinson — the same tradition as Epitalon, Cortexin, and Thymalin. It's marketed for brain protection and cognition, with claims of direct gene-expression effects.

Two honest caveats frame everything below: this class's defining mechanism (peptides directly regulating DNA) is not broadly accepted outside the Russian literature, and the human evidence is thin. It is not FDA-approved; everything here is research context, not medical guidance.

Pinealon is a synthetic tripeptide — Glu-Asp-Arg (EDR), ~418 Da, just three amino acids — making it one of the smallest peptides in research use. Like the rest of the Khavinson bioregulator family, it is proposed to act at very low concentrations.

Its small size is cited as the basis for cell penetration and (in the family's framing) for reaching the cell nucleus to influence gene expression — a claim that should be treated as hypothesis, not established fact.

The proposed mechanism is direct interaction with DNA to modulate the expression of genes involved in neuroprotection and antioxidant defense. In preclinical models, EDR has been associated with preserved dendritic spines (via MAPK/ERK signaling), modulation of hippocampal NMDA-receptor expression, and reduced oxidative stress. It's important to be clear that the 'peptide binds DNA to switch genes on/off' framing central to this family is not well supported in mainstream molecular biology — the downstream effects observed in animals may operate through other pathways.

There is no approved dosing, and the reported protocols are internally inconsistent — note the large gap between the 'neuroprotection' milligram dose and the 'cognitive' microgram dose (roughly a 17–50× difference), which is a red flag for unreliable dosing data.

• Neuroprotection (as reported): ~5 mg daily, subcutaneous
• Cognitive enhancement (as reported): ~100–300 mcg daily or every other day
• Anti-aging course: ~5 mg daily for ~20 days, 2–3× per year

The ~17–50× discrepancy between the mg and mcg protocols is unexplained — treat the dosing here as poorly characterized.

• Reconstitute with bacteriostatic water down the vial wall; swirl gently, never shake; solution should be clear.
• Refrigerate at 2–8°C and use within ~30 days; reject yellow/brown discoloration (degradation).

Published safety data is sparse. Reported effects are mild (occasional fatigue or headache, minimal injection-site reactions). Given the limited human data and the unsettled mechanism, this should be treated as an experimental compound; sterile technique and site rotation are standard precautions. Not recommended in pregnancy/breastfeeding.

• 5xFAD Alzheimer's mouse model (2021, ~400 µg/kg IP, 28 days): prevented dendritic spine loss via MAPK/ERK.
• Diabetic rat spatial learning (2020): increased hippocampal NMDA-receptor expression at low doses.
• Antioxidant modulation (2019, cell/animal): reduced reactive oxygen species.

These are animal and cell results from largely Russian-authored work. The human '72-patient TBI' claim cited on vendor pages is not among the verifiable references — confirm it independently before relying on it.

Pinealon is not FDA-approved and is sold as a research chemical for laboratory use only, not intended for human consumption. It has a history of use in Russia within the bioregulator tradition.

On the Huberman Lab podcast, Dr. Huberman and Dr. Abud Bakri made one useful factual correction: despite the name, pinealon (the tripeptide Glu-Asp-Arg, nicknamed 'EDR') is NOT derived from the pineal gland — it comes from a brain-cortex extract. (Epitalon is the pineal one.)

Dr. Huberman shared a striking PERSONAL, anecdotal observation: taken at the start of the night, pinealon reduced his deep slow-wave sleep and left him groggy, but a tiny mid-night dose roughly doubled his REM in the remaining hours, with the effect lingering for subsequent nights. He stressed he does this rarely (a few times a month) and that the Russian literature never even mentions REM. Treat this as one well-instrumented individual's experience, not a finding. Bakri also flagged mild blood-sugar drops as a reported effect.

A single person's tracked experience plus expert commentary — a hypothesis to test, not evidence of a reliable REM effect.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.